We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Dean Seal Mesoblast said regulators have granted their rare pediatric disease designation to its cell therapy Revascor for children with hypoplastic left heart syndrome. The Australian...
By Colin Kellaher American depositary shares of Mesoblast plummeted more than 65% in premarket trading Friday after the biopharmaceutical company's latest setback in its bid to win U.S. Food...
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed PDUFA Goal Date August 2, 2023 If Approved, Remestemcel-L will be...
By Colin Kellaher American depositary shares of Mesoblast Ltd. jumped more than 15% in early trading Wednesday after the biopharmaceutical company said the U.S. Food and Drug Administration...
By Chris Wack Mesoblast Ltd. shares were up 11% to $3.67 Wednesday after the company said it resubmitted a biologics license application to the U.S. Food and Drug Administration seeking approval...
By Chris Wack Mesoblast Ltd. shares were up 10% to $2.80 after the company said it submitted substantial new information to the U.S. Food and Drug Administration on clinical and potency assay...
By Chris Wack Mesoblast Ltd. said it has filed a request and expects to hold a Type C meeting with the U.S. Food & Drug Administration during the current quarter to discuss the pathway to U.S...
By Josh Beckerman Mesoblast Ltd. American depositary receipts surged 25% to $14.70 after hours as the company entered an exclusive worldwide license and collaboration agreement with Novartis AG...
Mesoblast Limited has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry. Mesoblast is a biopharma company specializing in cell...
MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.72 | 40 | 1.8 | 3.09 | 1.8 | 20407061 | 2.6005543 | DE |
4 | 1 | 65.7894736842 | 1.52 | 3.09 | 1.5 | 10293614 | 2.15619985 | DE |
12 | 1.39 | 123.008849558 | 1.13 | 3.09 | 1.13 | 6624068 | 1.81809928 | DE |
26 | 1.49 | 144.660194175 | 1.03 | 3.09 | 0.88 | 6036696 | 1.44229354 | DE |
52 | 2.22 | 740 | 0.3 | 3.09 | 0.255 | 7109225 | 1.06143556 | DE |
156 | 1.155 | 84.6153846154 | 1.365 | 3.09 | 0.255 | 3970341 | 0.93035176 | DE |
260 | 0.51 | 25.3731343284 | 2.01 | 5.7 | 0.255 | 4517949 | 1.93926892 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions